Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Hematologic manifestations of HIV infection: Anemia

Timothy J Friel, MD
David T Scadden, MD
Section Editor
Stanley L Schrier, MD
Deputy Editor
Jennifer S Tirnauer, MD


Shortly after the first description of the acquired immunodeficiency syndrome (AIDS), cytopenias of all major blood cell lines were increasingly recognized in patients with HIV infection. As an example, in one early series of patients with AIDS, anemia was noted in approximately 70 percent, lymphopenia in 70 percent, neutropenia in 50 percent, and thrombocytopenia in 40 percent [1].

The incidence of the various cytopenias correlates directly with the degree of immunosuppression. However, isolated abnormalities, particularly thrombocytopenia, may be encountered as the initial presentation of human immunodeficiency virus (HIV) infection. As a result, HIV infection should be considered in the assessment of patients presenting with any type of cytopenia.

The causes and treatment of anemia in patients with HIV infection will be reviewed here. Similar issues regarding neutropenia, thrombocytopenia, coagulation defects, and lymphopenia are discussed separately. (See "Hematologic manifestations of HIV infection: Neutropenia" and "Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities" and "Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients".)


Anemia is the most common hematologic abnormality associated with HIV infection, affecting 60 to 80 percent of patients in late stage disease. While anemia may manifest as a mere laboratory abnormality in some individuals, others may experience typical symptoms (eg, fatigue, dyspnea, reduced exercise tolerance, diminished functional capacity) directly related to a reduction in hemoglobin concentration. (See "Approach to the adult patient with anemia".)

In a review of more than 32,000 patients infected with HIV, the yearly incidence of developing anemia increased with disease progression, affecting 3 percent of all patients with asymptomatic HIV infection, 12 percent of asymptomatic patients with CD4 cell counts <200/microL, and 37 percent of patients with an AIDS-related illness [2].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jun 08, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Zon LI, Arkin C, Groopman JE. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol 1987; 66:251.
  2. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91:301.
  3. Martin C, Poudel-Tandukar K, Poudel KC. HIV symptom burden and anemia among HIV-positive individuals: cross-sectional results of a community-based positive living with HIV (POLH) study in Nepal. PLoS One 2014; 9:e116263.
  4. Berhane K, Karim R, Cohen MH, et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 37:1245.
  5. Wenger JD, Whalen CC, Lederman MM, et al. Prognostic factors in acquired immunodeficiency syndrome. J Gen Intern Med 1988; 3:464.
  6. Sathe SS, Gascon P, Lo W, et al. Severe anemia is an important negative predictor for survival with disseminated Mycobacterium avium-intracellulare in acquired immunodeficiency syndrome. Am Rev Respir Dis 1990; 142:1306.
  7. Moore RD. Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. Semin Hematol 2000; 37:18.
  8. O'Brien ME, Kupka R, Msamanga GI, et al. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005; 40:219.
  9. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2008; 22:97.
  10. Semba RD, Shah N, Klein RS, et al. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002; 34:260.
  11. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999; 13:943.
  12. Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013. Hematology Am Soc Hematol Educ Program 2013; 2013:377.
  13. Mootsikapun P, Srikulbutr S. Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome. Int J Infect Dis 2006; 10:66.
  14. van Elsacker-Neile AM, Kroon FP, van der Ende ME, et al. Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23:1255.
  15. Chernak E, Dubin G, Henry D, et al. Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 20:170.
  16. Abkowitz JL, Brown KE, Wood RW, et al. Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis 1997; 176:269.
  17. Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric Castleman's disease. Am J Hematol 2008; 83:498.
  18. Hepburn MJ, Dyal K, Runser LA, et al. Low serum vitamin B12 levels in an outpatient HIV-infected population. Int J STD AIDS 2004; 15:127.
  19. Burkes RL, Cohen H, Krailo M, et al. Low serum cobalamin levels occur frequently in the acquired immune deficiency syndrome and related disorders. Eur J Haematol 1987; 38:141.
  20. Shivakoti R, Christian P, Yang WT, et al. Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. Clin Nutr 2016; 35:183.
  21. Balfour L, Spaans JN, Fergusson D, et al. Micronutrient deficiency and treatment adherence in a randomized controlled trial of micronutrient supplementation in ART-naïve persons with HIV. PLoS One 2014; 9:e85607.
  22. Harriman GR, Smith PD, Horne MK, et al. Vitamin B12 malabsorption in patients with acquired immunodeficiency syndrome. Arch Intern Med 1989; 149:2039.
  23. Revell P, O'Doherty MJ, Tang A, Savidge GF. Folic acid absorption in patients infected with the human immunodeficiency virus. J Intern Med 1991; 230:227.
  24. Behler C, Shade S, Gregory K, et al. Anemia and HIV in the antiretroviral era: potential significance of testosterone. AIDS Res Hum Retroviruses 2005; 21:200.
  25. Sproat LO, Pantanowitz L, Lu CM, Dezube BJ. Human immunodeficiency virus-associated hemophagocytosis with iron-deficiency anemia and massive splenomegaly. Clin Infect Dis 2003; 37:e170.
  26. Lai M, Visconti E, D'Onofrio G, et al. Lower hemoglobin levels in human immunodeficiency virus-infected patients with a positive direct antiglobulin test (DAT): relationship with DAT strength and clinical stages. Transfusion 2006; 46:1237.
  27. Toy PT, Reid ME, Burns M. Positive direct antiglobulin test associated with hyperglobulinemia in acquired immunodeficiency syndrome (AIDS). Am J Hematol 1985; 19:145.
  28. McGinniss MH, Macher AM, Rook AH, Alter HJ. Red cell autoantibodies in patients with acquired immune deficiency syndrome. Transfusion 1986; 26:405.
  29. Telen MJ, Roberts KB, Bartlett JA. HIV-associated autoimmune hemolytic anemia: report of a case and review of the literature. J Acquir Immune Defic Syndr 1990; 3:933.
  30. Iordache L, Launay O, Bouchaud O, et al. Autoimmune diseases in HIV-infected patients: 52 cases and literature review. Autoimmun Rev 2014; 13:850.
  31. Virtue MA, Furne JK, Ho SB, Levitt MD. Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival. Am J Hematol 2004; 76:107.
  32. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47:694.
  33. Mira JA, López-Cortés LF, Merino D, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther 2007; 12:1225.
  34. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192.
  35. Snower DP, Weil SC. Changing etiology of macrocytosis. Zidovudine as a frequent causative factor. Am J Clin Pathol 1993; 99:57.
  36. Eyer-Silva WA, Arabe J, Pinto JF, Morais-De-Sá CA. Macrocytosis in patients on stavudine. Scand J Infect Dis 2001; 33:239.
  37. Duong M, Piroth L, Peytavin G, et al. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis 2001; 33:386.
  38. Khawcharoenporn T, Shikuma CM, Williams AE, Chow DC. Lamivudine-associated macrocytosis in HIV-infected patients. Int J STD AIDS 2007; 18:39.
  39. Scadden DT, Zon LI, Groopman JE. Pathophysiology and management of HIV-associated hematologic disorders. Blood 1989; 74:1455.
  40. Folks TM, Kessler SW, Orenstein JM, et al. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988; 242:919.
  41. Chelucci C, Hassan HJ, Locardi C, et al. In vitro human immunodeficiency virus-1 infection of purified hematopoietic progenitors in single-cell culture. Blood 1995; 85:1181.
  42. Molina JM, Scadden DT, Sakaguchi M, et al. Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. Blood 1990; 76:2476.
  43. Neal TF, Holland HK, Baum CM, et al. CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995; 86:1749.
  44. Shen H, Cheng T, Preffer FI, et al. Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. J Virol 1999; 73:728.
  45. Redd AD, Avalos A, Essex M. Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa. Blood 2007; 110:3143.
  46. Costantini A, Giuliodoro S, Butini L, et al. Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. J Acquir Immune Defic Syndr 2009; 52:70.
  47. Castella A, Croxson TS, Mildvan D, et al. The bone marrow in AIDS. A histologic, hematologic, and microbiologic study. Am J Clin Pathol 1985; 84:425.
  48. Spivak JL, Bender BS, Quinn TC. Hematologic abnormalities in the acquired immune deficiency syndrome. Am J Med 1984; 77:224.
  49. Karcher DS, Frost AR. The bone marrow in human immunodeficiency virus (HIV)-related disease. Morphology and clinical correlation. Am J Clin Pathol 1991; 95:63.
  50. Llewelyn MJ, Noursedeghi M, Dogan A, et al. Diagnostic utility of bone marrow sampling in HIV-infected patients since the advent of highly active antiretroviral therapy. Int J STD AIDS 2005; 16:686.
  51. Kilby JM, Marques MB, Jaye DL, et al. The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections. Am J Med 1998; 104:123.
  52. Buskin SE, Sullivan PS. Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus. Transfusion 2004; 44:826.
  53. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:54.
  54. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:315.
  55. Semba RD, Shah N, Klein RS, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDS 2001; 15:473.
  56. Sullivan PS, Hanson DL, Brooks JT. Impact on hemoglobin of starting combination antiretroviral therapy with or without zidovudine in anemic HIV-infected patients. J Acquir Immune Defic Syndr 2008; 48:163.
  57. van Prooijen HC, Visser JJ, van Oostendorp WR, et al. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994; 87:144.
  58. Kruskall MS, Lee TH, Assmann SF, et al. Survival of transfused donor white blood cells in HIV-infected recipients. Blood 2001; 98:272.
  59. Mudido PM, Georges D, Dorazio D, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996; 36:860.
  60. Seremetis SV, Aledort LM, Bergman GE, et al. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet 1993; 342:700.
  61. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993; 33:111.
  62. Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001; 285:1592.
  63. Asmuth DM, Kalish LA, Laycock ME, et al. Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. Transfusion 2003; 43:451.
  64. Drew WL, Chou S, Mohr BA, et al. Absence of activation of CMV by blood transfusion to HIV-infected, CMV-seropositive patients. Transfusion 2003; 43:1351.
  65. Henry DH, Volberding PA, Leitz G. Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future. J Acquir Immune Defic Syndr 2004; 37:1221.
  66. Marti-Carvajal AJ, Sola I. Treatment for anemia in people with AIDS. Cochrane Database Syst Rev 2007; CD004776.
  67. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 1992; 117:739.
  68. Phair JP, Abels RI, McNeill MV, Sullivan DJ. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results. Arch Intern Med 1993; 153:2669.
  69. Saag MS, Bowers P, Leitz GJ, et al. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients. AIDS Res Hum Retroviruses 2004; 20:1037.
  70. Volberding P. Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group. Clin Ther 2000; 22:1004.
  71. Grossman HA, Goon B, Bowers P, et al. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34:368.